Study guide
Section 4.7: Clinical Pharmacology: Renal & Urological Disorders
Saudi Pharmacist Licensure Examination SPLE - Pharmacist
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
Section 0.1: About the Saudi Pharmacist Licensure Examination (SPLE) Section 0.2: How to Study and Prep for the SPLE
2 Chapter 1: Basic Biomedical Sciences
Section 1.1: Human Physiology & Pathophysiology Foundations Section 1.2: Medical Biochemistry & Enzymology Section 1.3: Medical Microbiology & Immunology Section 1.4: Molecular Genetics & Pharmacogenomics Foundations
3 Chapter 2: Pharmaceutical Sciences
Section 2.1: Medicinal Chemistry & Structure-Activity Relationships (SAR) Section 2.2: Drug ADME (Absorption, Distribution, Metabolism, Excretion) Section 2.3: General Pharmacology: Mechanisms of Drug Action Section 2.4: General Toxicology: Overdose, Antidotes & Adverse Drug Reactions (ADRs) Section 2.5: Pharmacognosy: Natural Products & Dietary Supplements Section 2.6: Basic Pharmaceutics & Dosage Form Design Section 2.7: Biopharmaceutics & Drug Delivery Systems Section 2.8: Applied Pharmacokinetics (PK): One-Compartment Models Section 2.9: Non-linear and Multi-compartment Pharmacokinetics Section 2.10: Sterile Compounding: Techniques & Quality Standards Section 2.11: Non-sterile Compounding & Product Formulation Section 2.12: Pharmaceutical Calculations: Dosing and Strengths Section 2.13: Pharmaceutical Calculations: Dilutions and Reconstitution Section 2.14: Pharmaceutical Calculations: Osmolarity, Milliequivalents, and Alligations
4 Chapter 3: Social, Behavioral, and Administrative Sciences
Section 3.1: Saudi Arabian Healthcare System & Public Health Policies Section 3.2: Pharmacoepidemiology & Post-Marketing Drug Surveillance Section 3.3: Pharmacovigilance & Drug Safety Monitoring in Saudi Arabia Section 3.4: Pharmacoeconomic Principles & Cost-Benefit Analysis Section 3.5: Pharmacy Management, Inventory, and Operations Section 3.6: Saudi Pharmacy Law & SFDA Regulations Section 3.7: Biostatistics, Clinical Trial Design & Literature Evaluation Section 3.8: Professional Ethics, Communication, and Dispensing Systems
5 Chapter 4: Clinical Sciences
Section 4.1: Drug Information Services & Evidence-Based Medicine Section 4.2: Clinical Pharmacokinetics & Therapeutic Drug Monitoring (TDM) Section 4.3: Clinical Pharmacogenomics & Personalized Therapeutics Section 4.4: Disease Prevention, Wellness, and Immunization Schedules Section 4.5: Patient Assessment & Physical Examination Interpretation Section 4.6: Clinical Pharmacology: Cardiovascular Disorders Section 4.7: Clinical Pharmacology: Renal & Urological Disorders Section 4.8: Clinical Pharmacology: Respiratory & Pulmonary Disorders Section 4.9: Clinical Pharmacology: Endocrine & Metabolic Disorders Section 4.10: Clinical Pharmacology: Infectious Diseases & Antimicrobial Stewardship Section 4.11: Clinical Pharmacology: Neurological & Psychiatric Disorders Section 4.12: Clinical Pharmacology: Oncology, Immunology, and Hematology Section 4.13: Clinical Pharmacology: Gastrointestinal & Hepatic Disorders Section 4.14: Therapeutic Decision-Making in Special Populations (Geriatrics, Pediatrics, Pregnancy, Lactation)
Section 4.7: Clinical Pharmacology: Renal & Urological Disorders
Key Takeaways Explain This Topic AI
Drug-induced AKI can be prerenal (e.g., NSAIDs, ACEIs/ARBs), intrinsic ATN (e.g., aminoglycosides, cisplatin), or intrinsic AIN (e.g., beta-lactams, PPIs).
Managing anemia in CKD requires maintaining hemoglobin levels between 10-11 g/dL with ESAs, provided iron stores are replete, to avoid thromboembolic risks.
Hemodialysis drug clearance is determined by molecular weight, protein binding, water solubility, and volume of distribution.
BPH treatment utilizes alpha-blockers for rapid symptom relief (days) and 5-alpha reductase inhibitors for long-term gland shrinkage (3-6 months).
Last updated: July 2026
- Clinical Pharmacology: Renal & Urological Disorders
- Acute Kidney Injury (AKI)
AKI is a rapid decline in kidney function characterized by a rise in serum creatinine (SCr) and/or a decline in urine output.
KDIGO Staging :
Stage 1 : SCr increase of ≥ 0.3 mg/dL \ge 0.3 \text{ mg/dL} ≥ 0.3 mg/dL within 48 hours or 1.5 – 1.9 × 1.5\text{–}1.9 \times 1.5 – 1.9 × baseline.
Stage 2 : SCr increase of 2.0 – 2.9 × 2.0\text{–}2.9 \times 2.0 – 2.9 × baseline.
Stage 3 : SCr increase of ≥ 3.0 × \ge 3.0 \times ≥ 3.0 × baseline, SCr ≥ 4.0 mg/dL \ge 4.0 \text{ mg/dL} ≥ 4.0 mg/dL , or initiation of renal replacement therapy.
Classifications and Drug-Induced Causes :
Prerenal AKI : Caused by renal hypoperfusion. Drug causes include NSAIDs (block prostaglandin-mediated afferent arteriole vasodilation) and ACEIs/ARBs (block angiotensin II-mediated efferent arteriole vasoconstriction).
Intrinsic AKI (Acute Tubular Necrosis - ATN) : Direct damage to tubular cells. Drug causes include Aminoglycosides , Amphotericin B , Cisplatin , and Radiocontrast dye .
Intrinsic AKI (Acute Interstitial Nephritis - AIN) : Immune-mediated hypersensitivity. Drug causes include Beta-lactams , PPIs , and NSAIDs .
Postrenal AKI : Obstruction of urine flow (e.g., anticholinergic drugs causing urinary retention, or acyclovir/sulfonamides crystallizing in tubules).
Chronic Kidney Disease (CKD) Dosing and Complications
CKD is defined as kidney damage or GFR < 60 mL/min/1.73 m 2 < 60 \text{ mL/min/1.73 m}^2 < 60 mL/min/1.73 m 2 for ≥ 3 \ge 3 ≥ 3 months. Dosing adjustments are required for renally cleared drugs (e.g., gabapentin, enoxaparin, fluoroquinolones, metformin) to prevent accumulation and toxicity.
Anemia of CKD : Caused by decreased erythropoietin production by the kidneys.
Treatment : Erythropoietin-Stimulating Agents (ESAs) like epoetin alfa or darbepoetin alfa.
Clinical Safety : Initiate ESAs only when Hb < 10 g/dL \text{Hb} < 10 \text{ g/dL} Hb < 10 g/dL and target a range of 10 – 11 g/dL 10\text{–}11 \text{ g/dL} 10 – 11 g/dL . Do not exceed 11 g/dL 11 \text{ g/dL} 11 g/dL due to increased risks of stroke, cardiovascular events, and death. Ensure iron stores are adequate (ferritin > 500 ng/mL > 500 \text{ ng/mL} > 500 ng/mL , TSAT > 30 % > 30\% > 30% ) prior to starting ESAs.
CKD Mineral and Bone Disorder (CKD-MBD) : Hyperphosphatemia develops due to decreased renal phosphorus excretion. High phosphorus stimulates parathyroid hormone (PTH) release, causing secondary hyperparathyroidism and osteodystrophy.
Phosphate Binders : Must be taken with meals to bind dietary phosphate: calcium-based binders (Calcium Acetate, Calcium Carbonate) carry a risk of hypercalcemia and vascular calcification, while non-calcium-based binders (Sevelamer Carbonate, Lanthanum Carbonate) are preferred in patients with hypercalcemia or arterial calcification.
Vitamin D Analogs : Active vitamin D ( Calcitriol ) or analogs (paricalcitol) suppress PTH but can increase calcium and phosphate absorption.
Calcimimetics : Cinacalcet increases the sensitivity of calcium-sensing receptors on the parathyroid gland, reducing PTH secretion without raising calcium levels.
Renal Replacement Therapy (RRT) & Drug Dialyzability
In patients on hemodialysis (HD), drug clearance during a session depends on:
Molecular Weight : Smaller molecules ( < 500 Daltons < 500 \text{ Daltons} < 500 Daltons ) are easily cleared; large molecules (like vancomycin, ∼ 1450 Daltons \sim 1450 \text{ Daltons} ∼ 1450 Daltons ) are poorly cleared by traditional dialyzers.
Volume of Distribution ( V d V_d V d ) : Drugs with small V d V_d V d ( < 1 L/kg < 1 \text{ L/kg} < 1 L/kg ) remain in the blood and are dialyzable. Drugs with large V d V_d V d ( > 2 – 5 L/kg > 2\text{–}5 \text{ L/kg} > 2 – 5 L/kg ) reside in tissues and are not removed.
Protein Binding : Only unbound (free) drug is filtered. Highly protein-bound drugs ( > 80 % > 80\% > 80% ) are not dialyzable.
Water Solubility : Highly water-soluble drugs are more readily cleared than lipid-soluble ones.
Dialyzer Membrane : High-flux membranes have larger pore sizes and clear more drugs.
Urinary Tract Infections (UTIs)
Uncomplicated Cystitis : Occurs in healthy, non-pregnant, premenopausal females. First-line therapies:
Nitrofurantoin Monohydrate/Macrocrystals 100 mg BID for 5 days. Note : Contraindicated if CrCl < 30 mL/min \text{CrCl} < 30 \text{ mL/min} CrCl < 30 mL/min due to lack of efficacy (insufficient concentration in urine).
Trimethoprim/Sulfamethoxazole (TMP/SMX) 160/800 mg (DS) BID for 3 days.
Fosfomycin 3 g orally as a single dose.
Complicated Cystitis / Pyelonephritis : Treated with fluoroquinolones (Ciprofloxacin or Levofloxacin) or IV beta-lactams (e.g., Ceftriaxone) for 7–14 days.
Benign Prostatic Hyperplasia (BPH)
BPH management targets static (enlarged prostate) and dynamic (smooth muscle tone) obstruction of the bladder neck.
Alpha-1 Adrenergic Antagonists : Relax smooth muscle in the bladder neck and prostate.
Selective α 1 A \alpha_{1A} α 1 A Blockers (Tamsulosin, Silodosin): Minimal systemic blood pressure effects. Side effects include retrograde ejaculation and floppy iris syndrome (avoid starting before cataract surgery).
Non-selective α 1 \alpha_1 α 1 Blockers (Terazosin, Doxazosin): Cause vasodilation. Side effects include orthostatic hypotension, dizziness, and syncope. Dose must be titrated slowly and administered at bedtime.
Onset : Rapid symptom relief (within days).
5-Alpha Reductase Inhibitors (5-ARIs) : Block conversion of testosterone to dihydrotestosterone (DHT), shrinking the prostate gland.
Agents : Finasteride, Dutasteride.
Onset : Slow (takes 3 to 6 months to see benefit).
Clinical Safety : Teratogenic. Pregnant women or women of childbearing potential should not touch or handle crushed/broken tablets due to risk of absorption and feminization of a male fetus.
BPH Drug Class Examples Mechanism Onset of Action Key Side Effects
Selective α 1 A \alpha_{1A} α 1 A Blockers Tamsulosin, Silodosin Relax smooth muscle in prostate/bladder Rapid (days) Retrograde ejaculation, Floppy Iris Syndrome
Non-selective α 1 \alpha_1 α 1 Blockers Doxazosin, Terazosin Relax smooth muscle + peripheral vasodilation Rapid (days) Orthostatic hypotension, dizziness, syncope
5-Alpha Reductase Inhibitors Finasteride, Dutasteride Shrink prostate by blocking DHT synthesis Slow (3-6 months) Erectile dysfunction, gynecomastia, teratogenesis